Keyword Search Results for "anticoagulant"

Antman, E. M. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial Circulation. 1994;90:1624-30. Abstract

Becker, R. C., Cannon, C. P. Hirudin: Its Biology and Clinical Use J Thromb Thrombolysis. 1994;1(1):16-Jul. Abstract

Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol. 1994;23:993-1003. Abstract

Flaker, G. C., Bartolozzi, J., Davis, V., McCabe, C., Cannon, C. P. Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction. TIMI 4 investigators. Thrombolysis in Myocardial Infarction Archives of internal medicine. 1994;154(13):1492-6. Abstract

Cannon, C. P. Hirudin in Acute Myocardial Infarction J Thromb Thrombolysis. 1995;1(3):259-267. Abstract

Cannon, C. P., Braunwald, E. Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty J Am Coll Cardiol. 1995;25(7 Suppl):30S-37S. Abstract

Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation. 1995;92:727-33. Abstract

Lee, LV. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial Am J Cardiol. 1995;75:7-13. Abstract

Antman, E. M. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial Circulation. 1996;94:911-21. Abstract

Antman, E. M., Braunwald, E. Trials and tribulations of thrombin inhibition European heart journal. 1996;17(7):971-3.

Antman, E. M. Another chapter of the antithrombin story has been written European heart journal. 1997;18(9):1365-7.

Giugliano, R. P., Antman, E. M., Braunwald, E. Reexamination of the Thrombin Hypothesis: What We Have Learned from TIMI 9B and GUSTO IIb Journal of thrombosis and thrombolysis. 1997;4(4-Mar):321-323.

The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol. 1997;29:1474-82. Abstract

Antman, E. M. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators Am Heart J. 1998;135(6, Supplement 2):S353-60. Abstract

Antman, E. M., Sacks, D. B., Rifai, N., McCabe, C. H., Cannon, C. P., Braunwald, E. Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy J Am Coll Cardiol. 1998;31(2):326-30. Abstract

Morrow, D. A., Rifai, N., Antman, E. M., Weiner, D. L., McCabe, C. H., Cannon, C. P., Braunwald, E. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction J Am Coll Cardiol. 1998;31(7):1460-5. Abstract

Tracy, R. P., Kleiman, N. S., Thompson, B., Cannon, C. P., Bovill, E. G., Brown, R. G., Collen, D., Mahan, E., Mann, K. G., Rogers, W. J., Sopko, G., Stump, D. C., Williams, D. O., Zaret, B. L. Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial American heart journal. 1998;135(1):29-37. Abstract

Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation. 1999;100:1593-601. Abstract

Antman, E. M., Cohen, M., Radley, D., McCabe, C., Rush, J., Premmereur, J., Braunwald, E. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis Circulation. 1999;100(15):1602-8. Abstract

Becker, R. C., Hochman, J. S., Cannon, C. P., Spencer, F. A., Ball, S. P., Rizzo, M. J., Antman, E. M. Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study Journal of the American College of Cardiology. 1999;33(2):479-87. Abstract

Bozovich, G. E., Gurfinkel, E. P., Antman, E. M., McCabe, C. H., Mautner, B. Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time Am Heart J. 2000;140(4):637-42. Abstract

Cohen, M., Antman, E. M., Gurfinkel, E., Turpie, A. G., Furst, J., Bigonzi, F., Radley, D. Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction Am J Cardiol. 2000;86(5):553-6, A9. Abstract

Morrow, D. A., Antman, E. M., Tanasijevic, M., Rifai, N., de Lemos, J. A., McCabe, C. H., Cannon, C. P., Braunwald, E. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy J Am Coll Cardiol. 2000;36(6):1812-7. Abstract

Morrow, D. A., Rifai, N., Antman, E. M., Weiner, D. L., McCabe, C. H., Cannon, C. P., Braunwald, E. Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy J Am Coll Cardiol. 2000;35(2):358-62. Abstract

Cohen, M., Antman, E. M., Gurfinkel, E. P., Radley, D. Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups J Thromb Thrombolysis. 2001;12(3):199-206. Abstract

Henry, T. D., Satran, D., Knox, L. L., Iacarella, C. L., Laxson, D. D., Antman, E. M. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin? Am Heart J. 2001;142(4):590-3. Abstract

Antman EM, McCabe CH, Braunwald E. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. Am Heart J. 2002;143:229-34. Abstract

Antman, E. M., Cohen, M., McCabe, C., Goodman, S. G., Murphy, S. A., Braunwald, E. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE Eur Heart J. 2002;23(4):308-14. Abstract

Becker, R. C., Spencer, F. A., Gibson, M., Rush, J. E., Sanderink, G., Murphy, S. A., Ball, S. P., Antman, E. M. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes Am Heart J. 2002;143(5):753-9. Abstract

Cohen, M., Antman, E. M., Murphy, S. A., Radley, D. Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes Am Heart J. 2002;143(1):63-9. Abstract

Fox, K. A., Antman, E. M., Cohen, M., Bigonzi, F. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention Am J Cardiol. 2002;90(5):477-82. Abstract

NA, NA Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data Lancet. 2002;359(9303):294-302. Abstract

Spinler, S. A., Inverso, S. M., Cohen, M., Goodman, S. G., Stringer, K. A., Antman, E. M. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies Am Heart J. 2003;146(1):33-41. Abstract

Petersen, J. L., Mahaffey, K. W., Hasselblad, V., Antman, E. M., Cohen, M., Goodman, S. G., Langer, A., Blazing, M. A., Le-Moigne-Amrani, A., de Lemos, J. A., Nessel, C. C., Harrington, R. A., Ferguson, J. J., Braunwald, E., Califf, R. M. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview JAMA. 2004;292(1):89-96. Abstract

Giugliano, R. P., Wiviott, S. D., Stone, P. H., Simon, D. I., Schweiger, M. J., Bouchard, A., Leesar, M. A., Goulder, M. A., Deitcher, S. R., McCabe, C. H., Braunwald, E. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial J Am Coll Cardiol. 2007;49(25):2398-407. Abstract

Murphy, S. A., Gibson, C. M., Morrow, D. A., Van de Werf, F., Menown, I. B., Goodman, S. G., Mahaffey, K. W., Cohen, M., McCabe, C. H., Antman, E. M., Braunwald, E. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis Eur Heart J. 2007;28(17):2077-86. Abstract

Rich, J. D., Maraganore, J. M., Young, E., Lidon, R. M., Adelman, B., Bourdon, P., Charenkavanich, S., Hirsh, J., Theroux, P., Cannon, C. P. Heparin resistance in acute coronary syndromes J Thromb Thrombolysis. 2007;23(2):93-100. Abstract

Ruff, C. T., Wiviott, S. D., Morrow, D. A., Mohanavelu, S., Murphy, S. A., Antman, E. M., Braunwald, E. TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction American Journal of Medicine. 2007;120(11):993-8. Abstract

Yeh, R. W., Wiviott, S. D., Giugliano, R. P., Morrow, D. A., Shui, A., Qin, J., Scirica, B., Bradner, J. E., Jang, I. K., Gibson, C. M., Antman, E. M. Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes Am J Cardiol. 2007;100(12):1734-8. Abstract

Wiviott, S. D., Braunwald, E., McCabe, C. H., Horvath, I., Keltai, M., Herrman, J. P., Van de Werf, F., Downey, W. E., Scirica, B. M., Murphy, S. A., Antman, E. M. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial Lancet. 2008;371(9621):1353-63. Abstract

Gibson, C. M., Mega, J. L., Jennings, L. K., Mohanavelu, S., Misselwitz, F., Plotnikov, A., Sun, X., Zolynas, R., Braunwald, E. Effect of Rivaroxaban on Markers of Coagulation in Patients With Acute Coronary Syndromes: An ATLAS ACS-TIMI 46 Substudy Circulation. 2009;120(18):S1035-S1035.

Mega, J. L., Braunwald, E., Lee, M., Misselwitz, F., Mohanavelu, S., Notani, R., Peters, G., Gibson, C. M. Cessation of Rivaroxaban in Post-ACS Patients is Not Associated With Clinical Evidence of Rebound Hypercoagulability: An ATLAS ACS-TIMI 46 Substudy Circulation. 2009;120(18):S1002-S1002.

Mega, J. L., Braunwald, E., Mohanavelu, S., Burton, P., Poulter, R., Misselwitz, F., Hricak, V., Barnathan, E. S., Bordes, P., Witkowski, A., Markov, V., Oppenheimer, L., Gibson, C. M. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Lancet. 2009;374(9683):29-38. Abstract

Sabatine, M. S., Antman, E. M., Widimsky, P., Ebrahim, I. O., Kiss, R. G., Saaiman, A., Polasek, R., Contant, C. F., McCabe, C. H., Braunwald, E. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial Lancet. 2009;374(9692):787-95. Abstract

Thomas, D., Giugliano, R. P. ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy J Thromb Thrombolysis. 2009;27(1):10-Jan. Abstract

Giugliano, R. P., Giraldez, R. R., Morrow, D. A., Antman, E. M., Gibson, C. M., Mohanavelu, S., Murphy, S. A., McCabe, C. H., Braunwald, E. Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial Eur Heart J. 2010;31(17):2103-10. Abstract

Kadakia, M. B., Desai, N. R., Alexander, K. P., Chen, A. Y., Foody, J. M., Cannon, C. P., Wiviott, S. D., Scirica, B. M., National Cardiovascular Data, Registry Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines) JACC Cardiovasc Interv. 2010;3(11):1166-77. Abstract

Morrow, D. A., Antman, E. M., Fox, K. A., White, H. D., Giugliano, R., Murphy, S. A., McCabe, C. H., Braunwald, E. One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial European heart journal. 2010;31(17):2097-102. Abstract

Ruff, C. T., Braunwald, E. Will warfarin ever be replaced? J Cardiovasc Pharmacol Ther. 2010;15(3):210-9. Abstract

Ruff, C. T., Giugliano, R. P., Antman, E. M., Crugnale, S. E., Bocanegra, T., Mercuri, M., Hanyok, J., Patel, I., Shi, M., Salazar, D., McCabe, C. H., Braunwald, E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) Am Heart J. 2010;160(4):635-41. Abstract

Gibson, C. M., Mega, J. L., Burton, P., Goto, S., Verheugt, F., Bode, C., Plotnikov, A., Sun, X., Cook-Bruns, N., Braunwald, E. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome American heart journal. 2011;161(5):815-821 e6. Abstract

Ruff, Christian T., Goodman, Shaun, Hod, Hanoch, Bode, Christoph, Widimsky, Petr, Kiss, Robert G., Contant, Charles F., Crugnale, Sharon E., Moryusef, Angele, Steg, Gabriel, Antman, Elliott M., Sabatine, Marc S. Evaluation of the Efficacy and Safety of Otamixaban vs. Unfractionated Heparin+Eptifibatide in Elderly Patients with Non-St-Elevation Acute Coronary Syndromes in the SEPIA ACS-TIMI 42 Trial Journal of the American College of Cardiology. 2011;57(14, Supplement):E915.

Wiviott, S. D., Flather, M. D., O'Donoghue, M. L., Goto, S., Fitzgerald, D. J., Cura, F., Aylward, P., Guetta, V., Dudek, D., Contant, C. F., Angiolillo, D. J., Bhatt, D. L., Lancelot-Cad Investigators Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial Circulation. 2011;123(17):1854-63. Abstract

Gibson, C. Michael, Levitan, Bennett, Murphy, Sabina A, Yuan, Zhong, Chakrabarti, Anjan, Lee, Michael, Mega, Jessica, Braunwald, Eugene Abstract 13152: A Net Clinical Outcome Analysis Comparing Fatal or Irreversible Ischemic and Bleeding Events in ATLAS ACS 2 - TIMI 51 Circulation. 2012;126(21 Supplement):A13152.

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19. Abstract

Mega, Jessica L, Braunwald, Eugene, Wiviott, Stephen D, Murphy, Sabina, Plotnikov, Alexei, Gotcheva, Nina, Ruda, Mikhail, Gibson, C. Michael Abstract 16014: Evaluation of Cardiac Events in ATLAS ACS 2-TIMI 51 Circulation. 2012;126(21 Supplement):A16014.

Pride, Yuri, Mohanavelu, Satishkumar, Mega, Jessica, Braunwald, Eugene, Gibson, C. Michael Abstract 9944: Temporal Relationship Between Major Hemorrhagic Events and Mortality among Patients with Recent Acute Coronary Syndrome: Insights from ATLAS ACS 2-TIMI 51 Circulation. 2012;126(21 Supplement):A9944.

Steg, P. G., Mehta, S. R., Pollack, C. V., Jr., Bode, C., Gaudin, C., Fanouillere, K., Moryusef, A., Wiviott, S. D., Sabatine, M. S. Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy Am Heart J. 2012;164(6):817-24 e13. Abstract

Subherwal, S., Peterson, E. D., Chen, A. Y., Roe, M. T., Washam, J. B., Gage, B. F., Bach, R. G., Bhatt, D. L., Wiviott, S. D., Lopes, R. D., Alexander, K. P., Wang, T. Y. Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry Circulation. 2012;125(11):1414-23. Abstract

Cavender, M. A., Braunwald, E. B., Gibson, C. M., Wiviott, S., Murphy, S., Amuchastegui, A., Ophuis, A. J, van Hessen, M, Mega, J. L., Timi Study Group Rivaroxaban Reduces Spontaneous and Large Myocardial Infarctions: findings from the ATLAS ACS 2 - TIMI 51 Trial Journal of the American College of Cardiology. 2013;61(10):A1.

Dogliotti, A., Paolasso, E., Giugliano, R. P. Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients Heart. 2013;NA(NA):NA. Abstract

Dogliotti, A., Paolasso, E., Giugliano, R. P. Novel Oral Anticoagulants in Atrial Fibrillation: A Meta-analysis of Large, Randomized, Controlled Trials vs Warfarin Clin Cardiol. 2013;36(2):61-7. Abstract

Geller, B. J., Mega, J. L., Morrow, D. A., Guo, J., Hoffman, E. B., Gibson, C. M., Ruff, C. T. Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial J Thromb Thrombolysis. 2013;NA(NA):NA. Abstract

Gibson, C. M., Chakrabarti, A. K., Mega, J., Bode, C., Bassand, J. P., Verheugt, F. W., Bhatt, D. L., Goto, S., Cohen, M., Mohanavelu, S., Burton, P., Stone, G., Braunwald, E., Atlas-Acs Timi Investigators Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51 J Am Coll Cardiol. 2013;62(4):286-90. Abstract

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-104. Abstract

Grinstein, J., Bonaca, M., Sabatine, M., Jarolim, P., Conrad, M. J., Braunwald, E. B., Giugliano, R. P., Newby, L. K., Morrow, D. A., Timi Study Group, Prognostic Implications of Low-Level Cardiac Troponin Elevation Using the High-Sensitivity Assay for Cardiac Troponin T: Results from EARLY ACS & SEPIA-TIMI 42 Journal of the American College of Cardiology. 2013;61(10):A27.

Gupta, D. K., Shah, A. M., Giugliano, R. P., Ruff, C. T., Antman, E. M., Grip, L. T., Deenadayalu, N., Hoffman, E., Patel, I., Shi, M., Mercuri, M., Mitrovic, V., Braunwald, E., Solomon, S. D., for the Effective aNticoaGulation with factor x, A. next GEneration in A. F. Thrombolysis In Myocardial Infarction Echocardiographic Study Investigators Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48 Eur Heart J. 2013;NA(NA):NA. Abstract

Gupta, D.K., Shah, A., Giugliano, R., Ruff, C. T., Antman, E., Grip, L., Deenadayalu, N., Hoffman, Elaine P., Betcher, J., Patel, I., Shi, M., Braunwald, E., Solomon, S., ENGAGE AF-TIMI 48 Investigators Cardiac Structure and Function and CHADS2 Risk Score in Patients with Atrial Fibrillation: The Effective aNticoaGulation with factor xA next GEeration in AF-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) Journal of the American College of Cardiology. 2013;61(10):A237.

Mega, J. L., Braunwald, E. B., Murphy, S., Plotnikov, A, Cook-Bruns, N, Aylward, P., Chopra, V., Gao, R., Nicolau, J., Gibson, C. M., Timi Study Group Rivaroxaban in the Settling of continued Dual Antiplatelet Therapy: Findings from the ATLAS ACS 2 - TIMI 51 Trial Journal of the American College of Cardiology. 2013;61(10):A1.

Mega, J. L., Braunwald, E., Murphy, S. A., Plotnikov, A., Burton, P., Kiss, R. G., Parkhomenko, A., Tendera, M., Widimsky, P., Gibson, C. M. Rivaroxaban in Patients Stabilized after a ST-Elevation Myocardial Infarction: Results from the ATLAS ACS 2-TIMI 51 Trial J Am Coll Cardiol. 2013;NA(NA):NA. Abstract

Mega, J. L., Braunwald, E., Wiviott, S. D., Murphy, S. A., Plotnikov, A., Gotcheva, N., Ruda, M., Gibson, C. M. Comparison of the Efficacy and Safety of Two Rivaroxaban Doses in Acute Coronary Syndrome (from ATLAS ACS 2-TIMI 51) Am J Cardiol. 2013;NA(NA):NA. Abstract

Murphy, S. A., Giugliano, R. P. Atrial fibrillation and prior MI: searching for balance in ischaemic and bleeding events in patients treated with fibrin-specific anticoagulants Eur Heart J. 2013;NA(NA):NA.

Nerini, E., Grip, L., Camm, A. J., Giugliano, R. P. Atrial fibrillation and the 'other drug problem': reducing non-adherence with technology Eur Heart J. 2013;NA(NA):NA.

O'Donoghue, Michelle L, Mega, Jessica L, Braunwald, Eugene, Nicolau, Jose C, Bhatt, Deepak L, Murphy, Sabina A, Gibson, C. Michael Abstract 11382: The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial Circulation. 2013;128(22 Supplement):A11382.

Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., Yamashita, T., Antman, E. M. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet. 2013;NA(NA):NA. Abstract

Ruff, C. T., Moryusef, A, Umez-Eronini, A., Hoffman, Elain P., Gaudin, C., Antman, E., Sabatine, M., Timi Study Group Evaluation of the Efficacy and Safety of Otamixaban versus Unfractionated Heparin+Eptifibatide in Patients with Non-ST-Elevation Acute Coronary Syndromes by PCI in the SEPIA-ACS1 TIMI 42 Trial Journal of the American College of Cardiology. 2013;61(10):A25.

Steinberg, B. A., Beckley, P. D., Deering, T. F., Clark, C. L., Amin, A. N., Bauer, K. A., Cryer, B., Mansour, M., Scheiman, J. M., Zenati, M. A., Newby, L. K., Peacock, W. F., Bhatt, D. L., for the Society of Cardiovascular Patient, Care Evaluation and Management of the Atrial Fibrillation Patient: A Report From the Society of Cardiovascular Patient Care Crit Pathw Cardiol. 2013;12(3):107-115. Abstract

Bergmark, B., Giugliano, R. P. Perioperative management of target-specific oral anticoagulants Hosp Pract (1995). 2014;42(1):38-45. Abstract

Gonzalez-Quesada, C. J., Giugliano, R. P. Comparison of the Phase III Clinical Trial Designs of Novel Oral Anticoagulants Versus Warfarin for the Treatment of Nonvalvular Atrial Fibrillation: Implications for Clinical Practice Am J Cardiovasc Drugs. 2014;NA(NA):NA. Abstract

Gonzalez-Quesada, C. J., Giugliano, R. P. Erratum to: Comparison of the Phase III Clinical Trial Designs of Novel Oral Anticoagulants Versus Warfarin for the Treatment of Nonvalvular Atrial Fibrillation: Implications for Clinical Practice Am J Cardiovasc Drugs. 2014;NA(NA):NA.

Mega, J. L., Giugliano, R. P. Genotype-Guided Dosing of Warfarin Clin Chem. 2014;NA(NA):NA.

Plitt, A., Giugliano, R. P. Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation? Future Cardiol. 2014;10(2):153-5.

Plitt, A., Giugliano, R. P. Edoxaban: Review of Pharmacology and Key Phase I to III Clinical Trials J Cardiovasc Pharmacol Ther. 2014;NA(NA):NA. Abstract

Reddy, P., Giugliano, R. P. The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes J Cardiovasc Pharmacol Ther. 2014;NA(NA):NA. Abstract

Ruff, Christian T., Giugliano, Robert, Braunwald, Eugene, Morrow, David, Murphy, Sabina, Deenadayalu, Naveen, Jarolim, Petr, Betcher, Joshua, Shi, Minggao, Brown, Karen S., Patel, Indravadan, Mercuri, Michele, Antman, Elliott RELATIONSHIP BETWEEN DOSE, ANTI-FACTOR XA ACTIVITY, AND OUTCOMES IN PATIENTS RANDOMIZED TO EDOXABAN IN THE ENGAGE AF-TIMI 48 TRIAL Journal of the American College of Cardiology. 2014;63(12, Supplement):A329.